Literature DB >> 21146724

Novel bis-indole agents active against multidrug-resistant Acinetobacter baumannii.

Michael R Jacobs1, Saralee Bajaksouzian, Caryn E Good, Michelle M Butler, John D Williams, Norton P Peet, Terry L Bowlin, Andrea Endimiani, Robert A Bonomo.   

Abstract

The in vitro activity of 5 novel Microbiotix bis-indole agents (MBXs) (Microbiotix, Worcester, MA) against 30 multidrug-resistant (MDR) Acinetobacter baumannii (including 18 resistant to carbapenems) was evaluated. Overall, MIC(90)'s ranged from 1 to 8 μg/mL, whereas those for imipenem were >64 μg/mL. MBX 1196 was the most potent (MIC(90), 1 μg/mL). MBXs are compounds that are highly effective against MDR A. baumannii.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21146724      PMCID： PMC3725720          DOI： 10.1016/j.diagmicrobio.2010.08.014

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  5 in total

Review 1.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 2.  Acinetobacter infection.

Authors:  L Silvia Munoz-Price; Robert A Weinstein
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

3.  Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center.

Authors:  Kristine M Hujer; Andrea M Hujer; Edward A Hulten; Saralee Bajaksouzian; Jennifer M Adams; Curtis J Donskey; David J Ecker; Christian Massire; Mark W Eshoo; Rangarajan Sampath; Jodi M Thomson; Philip N Rather; David W Craft; Joel T Fishbain; Allesa J Ewell; Michael R Jacobs; David L Paterson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

Review 4.  An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii.

Authors:  Lenie Dijkshoorn; Alexandr Nemec; Harald Seifert
Journal:  Nat Rev Microbiol       Date:  2007-12       Impact factor: 60.633

5.  Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.

Authors:  Rekha G Panchal; Ricky L Ulrich; Douglas Lane; Michelle M Butler; Chad Houseweart; Timothy Opperman; John D Williams; Norton P Peet; Donald T Moir; Tam Nguyen; Rick Gussio; Terry Bowlin; Sina Bavari
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191
  5 in total
  4 in total

1.  Synthesis and antibacterial evaluation of new, unsymmetrical triaryl bisamidine compounds.

Authors:  Son T Nguyen; John D Williams; Michelle M Butler; Xiaoyuan Ding; Debra M Mills; Tommy F Tashjian; Rekha G Panchal; Susan K Weir; Chaeho Moon; Hwa-Ok Kim; Jeremiah A Marsden; Norton P Peet; Terry L Bowlin
Journal:  Bioorg Med Chem Lett       Date:  2014-06-12       Impact factor: 2.823

2.  Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds.

Authors:  Son T Nguyen; Steven M Kwasny; Xiaoyuan Ding; John D Williams; Norton P Peet; Terry L Bowlin; Timothy J Opperman
Journal:  Bioorg Med Chem       Date:  2015-07-14       Impact factor: 3.641

3.  DNA Targeting as a Likely Mechanism Underlying the Antibacterial Activity of Synthetic Bis-Indole Antibiotics.

Authors:  Timothy J Opperman; Steven M Kwasny; Jessica Bo Li; Mark A Lewis; Daniel Aiello; John D Williams; Norton P Peet; Donald T Moir; Terry L Bowlin; Eric C Long
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

4.  Rapid Killing and Biofilm Inhibition of Multidrug-Resistant Acinetobacter baumannii Strains and Other Microbes by Iodoindoles.

Authors:  Chaitany Jayprakash Raorane; Jin-Hyung Lee; Jintae Lee
Journal:  Biomolecules       Date:  2020-08-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.